The European Medicines Agency has agreed on major changes to its guidance that explains how companies should select additional risk minimization tools to address specific safety issues with their medicines and study the effectiveness of these tools.
The updated guideline, which will include “pages and pages” of new information on various tools for additional risk minimization, is...




